Skip to content

US · OMER · BIOTECHNOLOGY

Omeros Corporation (OMER) intrinsic value and stock valuation

$13.21as of 2026-11-21 · Mkt cap 958.97M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Omeros Corporation DCF and intrinsic value

InvestorsCraft values OMER with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OMER’s statements →

Omeros Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Seattle, WA 98119 omeros.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-3.35M
20112025
Free cash flow
-$-116.16M
20112025
Total equity
-$-121.23M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-122.8M-$-169.26M-$-164.53M-$-163.39M-$-173.62M
Net income-$-3.35M-$-156.81M-$-117.81M$47.4M-$-111.41M
EPSd-$-52.75K-$-2.7M-$-1.88M$755.8K-$-1.79M
Operating cash flow-$-116.09M-$-148.8M$74.7M-$-86.48M-$-109.72M
Capital expenditure-$-70K-$-170K-$-430K-$-110K-$-280K
Free cash flow-$-116.16M-$-148.97M$74.3M-$-86.6M-$-110M
Total assets$325.6M$277.1M$378.3M$591M$419.3M
Total debt$239.1M$207M$361.6M$342M$347.8M
Net debt$229.5M$203.6M$354.5M$331M$247M
Total equity-$-121.23M-$-182.61M-$-24.98M$85.7M$23.8M
Cash and short-term investments$171.8M$90.1M$171.9M$194.9M$157.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$1.39M
Gross profit$0.00$0.00$0.00$0.00-$-1.39M
Research and development expenses$81.3M$119.5M$114.9M$112.7M$118.8M
Selling, general and administrative expenses$41.5M$49.7M$49.7M$50.7M$53.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$122.8M$169.3M$164.5M$163.4M$172.2M
Cost and expenses$122.8M$169.3M$164.5M$163.4M$173.6M
Interest income$5.06M$11.3M$16.3M$4.06M$20K
Interest expense$0.00$24.7M$30.8M$22.7M$19.7M
Depreciation and amortization$960K$950K$920K$950K$1.39M
Ebitda-$-1.83M-$-157M-$-143.16M-$-158.38M-$-170.49M
Operating income-$-122.8M-$-169.26M-$-164.53M-$-163.39M-$-173.62M
Total other income/expenses, net$120M-$-13.37M-$-10.39M-$-18.64M-$-17.93M
Income before tax-$-2.8M-$-182.63M-$-174.92M-$-182.03M-$-191.55M
Income tax expense$2.01M$0.00$0.00$0.00$0.00
Net income-$-3.35M-$-156.81M-$-117.81M$47.4M-$-111.41M
Weighted average shares outstanding$63.5M$58.2M$62.7M$62.7M$62.3M
Weighted average diluted shares outstanding$63.5M$58.2M$62.7M$62.7M$62.3M
Balance sheet
20252024202320222021
Cash and short-term investments$171.8M$90.1M$171.9M$194.9M$157.3M
Net receivables$36.3M$36.8M$6.72M$242M$82.5M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$215.7M$134.1M$217.9M$443.2M$248M
Property, plant and equipment, net$12.5M$17.6M$20.6M$23.3M$30M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$110M$143M$160.4M$147.7M$171.3M
Total assets$325.6M$277.1M$378.3M$591M$419.3M
Accounts payable$4.76M$5.91M$7.71M$5.99M$13.4M
Short-term debt$23.4M$27M$13.7M$98.7M$5.25M
Deferred revenue$2.47M$0.00$0.00$0.00$0.00
Total current liabilities$78.1M$79.5M$53.3M$136.4M$51.8M
Long-term debt$215.8M$180.1M$347.9M$243.3M$342.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$368.8M$380.2M$349.9M$368.9M$343.7M
Capital lease obligations$13.5M$19.4M$23.3M$26.7M$34.4M
Total liabilities$446.9M$459.7M$403.3M$505.3M$395.5M
Common stock$720K$580K$610K$630K$630K
Retained earnings-$-913.7M-$-910.35M-$-753.53M-$-635.72M-$-683.13M
Accumulated other comprehensive income (loss)$0.00$0.00-$0.00$0.00$0.00
Total equity-$-121.23M-$-182.61M-$-24.98M$85.7M$23.8M
Total investments$162.1M$86.7M$164.7M$183.9M$56.5M
Total debt$239.1M$207M$361.6M$342M$347.8M
Net debt$229.5M$203.6M$354.5M$331M$247M
Cash flow statement
20252024202320222021
Net income-$-3.35M-$-156.81M-$-117.81M-$-182.03M-$-191.55M
Depreciation and amortization$960K$950K$920K$950K$1.39M
Stock-based compensation$8.19M$10.5M$11.7M$0.00$0.00
Change in working capital$33.7M$29.7M$247.4M-$-118.97M-$-14.11M
Accounts receivable$30.5M$40M$245.7M-$-175.07M-$-34.31M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00-$-10.66M$14.6M
Net cash provided by operating activities-$-116.09M-$-148.8M$74.7M-$-86.48M-$-109.72M
Investments in property, plant and equipment-$-70K-$-170K-$-430K-$-110K-$-280K
Acquisitions, net$0.00$0.00$0.00$0.00$126M
Net cash used for investing activities$164.5M$82.2M$27.5M-$-127.56M$193.7M
Common stock issued$47M$0.00$0.00$410K$8.38M
Common stock repurchased$0.00-$-11.85M-$-4.65M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-42.17M$62.9M-$-106.08M$124.3M$6.32M
Net change in cash$6.26M-$-3.71M-$-3.9M-$-89.8M$90.3M
Cash at end of period$9.66M$3.4M$7.11M$11M$100.8M
Operating cash flow-$-116.09M-$-148.8M$74.7M-$-86.48M-$-109.72M
Capital expenditure-$-70K-$-170K-$-430K-$-110K-$-280K
Free cash flow-$-116.16M-$-148.97M$74.3M-$-86.6M-$-110M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Omeros Corporation

        Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.

        CEO
        Gregory A. Demopulos
        Employees
        175
        Beta
        2.55

        Explore

        Frequently asked questions

        What is the intrinsic value of Omeros Corporation (OMER)?

        InvestorsCraft does not currently publish an intrinsic value for OMER. How the IC value is calculated.

        Is OMER undervalued?

        InvestorsCraft does not publish an undervaluation signal for OMER at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.